Atinuke Olaleye1, Babasola O Okusanya2, Olabisi Oduwole3, Ekpereonne Esu4, Martin Meremikwu5. 1. Maternal-Fetal Medicine Unit, Department of Obstetrics and Gynecology, Benjamin Carson (Sr) School of Medicine, Babcock University, Ilishan-Remo, Nigeria. 2. Experimental and Maternal Medicine Unit, Department of Obstetrics and Gynecology, Faculty of Clinical Sciences, College of Medicine, University of Lagos, Lagos, Nigeria. 3. Department of Medical Laboratory Science, Achievers University, Owo, Nigeria. 4. Department of Public Health, Faculty of Allied Medical Sciences, College of Medical Sciences, University of Calabar, Calabar, Nigeria. 5. Department of Pediatrics, College of Medical Sciences, University of Calabar, Calabar, Nigeria.
Abstract
BACKGROUND: Intermittent preventive treatment (IPT) with sulphadoxine-pyrimethamine (SP) is recommended for preventing maternal and fetal effects of malaria in pregnancy. Increasing parasite resistance to SP has necessitated the search for an alternative medication. OBJECTIVE: To compare dihydroartemisinin-piperaquine (DP) and sulphadoxine-pyrimethamine in preventing malaria during pregnancy. SEARCH STRATEGY: Databases including CENTRAL, MEDLINE, and ICTRP were searched until August 2018. SELECTION CRITERIA: Randomized and quasi-randomized controlled trials that compared DP with SP given to pregnant women to prevent adverse maternal or fetal effects of malaria were included. DATA COLLECTION AND ANALYSIS: Quality of evidence was determined with GRADE criteria. Effectiveness measures were calculated using odds ratios at 95% confidence intervals. RESULTS: Three randomized controlled trials were included. Compared with IPT-SP, moderate certainty evidence indicated that women who received IPT-DP had significantly lower risks of clinical malaria during pregnancy. High certainty evidence showed intermittent screening and treatment with DP did not reduce placental malaria or maternal parasitemia at delivery. Effect of DP on low birth weight and adverse birth outcomes was minimal. CONCLUSIONS: Moderate certainty evidence suggests that IPT-DP may reduce maternal and placental malaria compared with IPT-SP, and monthly DP is more effective than SP in reducing placental malaria. PROSPERO ID: CRD42018084651.
BACKGROUND: Intermittent preventive treatment (IPT) with sulphadoxine-pyrimethamine (SP) is recommended for preventing maternal and fetal effects of malaria in pregnancy. Increasing parasite resistance to SP has necessitated the search for an alternative medication. OBJECTIVE: To compare dihydroartemisinin-piperaquine (DP) and sulphadoxine-pyrimethamine in preventing malaria during pregnancy. SEARCH STRATEGY: Databases including CENTRAL, MEDLINE, and ICTRP were searched until August 2018. SELECTION CRITERIA: Randomized and quasi-randomized controlled trials that compared DP with SP given to pregnant women to prevent adverse maternal or fetal effects of malaria were included. DATA COLLECTION AND ANALYSIS: Quality of evidence was determined with GRADE criteria. Effectiveness measures were calculated using odds ratios at 95% confidence intervals. RESULTS: Three randomized controlled trials were included. Compared with IPT-SP, moderate certainty evidence indicated that women who received IPT-DP had significantly lower risks of clinical malaria during pregnancy. High certainty evidence showed intermittent screening and treatment with DP did not reduce placental malaria or maternal parasitemia at delivery. Effect of DP on low birth weight and adverse birth outcomes was minimal. CONCLUSIONS: Moderate certainty evidence suggests that IPT-DP may reduce maternal and placental malaria compared with IPT-SP, and monthly DP is more effective than SP in reducing placental malaria. PROSPERO ID: CRD42018084651.
Authors: Francesco Vladimiro Segala; Francesco Di Gennaro; Jerry Ictho; Mariangela L'Episcopia; Emmanuel Onapa; Claudia Marotta; Elda De Vita; James Amone; Valentina Iacobelli; Joseph Ogwang; Giovanni Dall'Oglio; Benedict Ngole; Rita Murri; Lameck Olal; Massimo Fantoni; Samuel Okori; Giovanni Putoto; Carlo Severini; Peter Lochoro; Annalisa Saracino Journal: BMC Infect Dis Date: 2022-08-04 Impact factor: 3.667
Authors: Liana R Andronescu; Ankur Sharma; Ingrid Peterson; Martin Kachingwe; Witness Kachepa; Yuanyuan Liang; Julie R Gutman; Don P Mathanga; Jobiba Chinkhumba; Miriam K Laufer Journal: J Infect Dis Date: 2022-01-18 Impact factor: 7.759